BioSpace News Archive

Ensysce Biosciences, Inc. announced that by decision dated February 14, 2023, a Nasdaq Hearings Panel granted the Company’s request for continued listing on The Nasdaq Stock Market, subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market tier, including the $1.00 bid price and $2.5 million stockholders’ equity requirements, by June 12, 2023, and the Company’s satisfaction of certain other interim conditions.

On February 9, 2023, the World Health Organization Director General convened a meeting of the International Health Regulations Emergency Committee on the multi-country outbreak of mpox to assess the ongoing international outbreak.

Axcella Therapeutics (Nasdaq: AXLA), today announced its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been cleared by the U.S. Food and Drug Administration (FDA).

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2022 financial results and provide a business update at 8:30 a.m. ET on Tuesday, February 28, 2023.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the fourth quarter and full year 2022, after market on Tuesday, February 28, 2023.

Today, Emergent BioSolutions Inc. (NYSE:EBS) announced the U.S. Food and Drug Administration (FDA) Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee have unanimously voted in favor (a total of 19 votes) that the benefit-risk profile of NARCAN® (naloxone HCl) Nasal Spray is supportive of its use as a nonprescription opioid overdose reversal agent.

Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.